Liraglutide: cost, evidence, and the honest comparison
The original GLP-1 for weight management. Same receptor family as semaglutide, but a daily injection with a shorter half-life — which is why the newer weekly drugs largely displaced it.
What it's approved for
Under the Saxenda brand and its generics, chronic weight management; under Victoza and its generics, type 2 diabetes. The first generic weight-loss version launched in 2025.
Forms and doses: Once-daily injection pen.
What the research actually shows
Average weight loss in liraglutide trials was meaningfully lower than semaglutide or tirzepatide achieved in theirs, which is why it moved to the background clinically. Its comeback story is economic, not clinical: generics arrived.
Sources: FDA label information (DailyMed)
Side effects, stated plainly
Gastrointestinal effects dominate, as with the class, and the daily injection schedule is its own adherence consideration. Class boxed warning applies.
What it costs
This is the one GLP-1 where discount cards genuinely shine: generic liraglutide has been priced as low as roughly $372 a month with a coupon against retail of $1,300 or more — a real coupon discount, unlike the brand GLP-1 quotes that merely echo manufacturer programs.
Keep reading
Common questions
Is generic liraglutide worth considering?
It is the cheapest true GLP-1 route via coupon, and the only one where discount cards do real work. The trade-offs are daily injections and lower average weight loss in trials than the newer drugs. Whether it fits is a prescriber conversation.
Other weight loss medications
Wegovy · Zepbound · Foundayo · Ozempic · Compounded semaglutide · Compounded tirzepatide
Liraglutide market news
The complaint targets sharing sensitive health data with ad platforms and ROSCA billing/cancellation practices — context for anyone weighing the $149/month membership model.
The Hims dossier →Participating Part D plans now cover Wegovy (pen and pill), Foundayo, and the Zepbound KwikPen at a flat $50 monthly copay through 2027 — below every cash price we track.
How the Bridge actually works →The proposed 503B Bulks List exclusion would close the mass-compounding era for good. Patient-specific 503A compounding continues — the legal market our index tracks at $139–$297 all-in.
The surviving market, explained →All tracked news → · Fed by a daily automated scan; entries publish only after primary-source verification.
Educational and pricing journalism, not medical advice — indications, dosing, and suitability are decisions for you and a licensed clinician, and the FDA label is the authority on risks. Prices carry the verification dates shown; the provider's checkout is the final word. Some links may earn commissions; rankings are ordered by cost, never compensation — disclosure.